Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05346146 | A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05329597 | Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer | unknown | — | 88 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER |
| 1 |
| Apr 15, 2022 |
| clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03958019 | Rehabilitation Strategies Following Oesophagogastric and Hepatopancreaticobiliary Cancer(RESTORE II) | unknown | N/A | 120 | University of Dublin, Trinity CollegeOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05320328 | RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION(MBOP) | unknown | — | 50 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05313854 | Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data | unknown | — | 1,000 | RenJi HospitalOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05178628 | The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer(imPaCT-PRO) | unknown | Phase 3 | 450 | Michalis KaramouzisOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05298020 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05289895 | Prognostic Biomarkers of Pancreatic Cancer Based on Proteomic Techniques | unknown | — | 220 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Mar 22, 2022 | clinicaltrials |
| NCT05253313 | Magnetic Resonance Imaging for Better Selection of Pancreatic Cancer Patients for Surgery: A Randomized Clinical Trial(MAGIPAC) | unknown | N/A | 200 | University of AarhusOTHER | 0 | Mar 16, 2022 | clinicaltrials |
| NCT05275062 | Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma | unknown | Early Phase 1 | 6 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05275985 | 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma | unknown | N/A | 80 | Peking Union Medical College HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 51 | Zhejiang UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05270564 | Post-operative Drainage After Pancreaticoduodenectomy(Drain 1) | unknown | N/A | 300 | Linkoeping UniversityOTHER_GOV | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05259384 | Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms | unknown | N/A | 120 | Peking Union Medical College HospitalOTHER | 1 | Feb 28, 2022 | clinicaltrials |
| NCT04812808 | Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma(BAZE) | unknown | N/A | 10 | Hôpital FribourgeoisOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05234450 | Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas(Camune) | unknown | — | 300 | University Hospital, Strasbourg, FranceOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05201729 | Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer | unknown | — | 30 | Ruijin HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05187416 | Correlation Between Elastic Modulus of Ultrasonic Shear Wave and Tumor Stromal Component in Pancreatic Cancer | unknown | — | 50 | Xijing HospitalOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05168527 | The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05192044 | Less Than 100 Hours Hospital Stay After Pancreatico-duodenectomy, RCT | unknown | N/A | 40 | National Cancer Institute, EgyptOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05185869 | SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer | unknown | Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03978702 | Evaluation of the Impact of Pancreatectomy on Systemic Immunity(IMMUNOPANC) | unknown | N/A | 40 | Institut Paoli-CalmettesOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT05095831 | EUS Shear Wave for Solid Pancreatic Lesions. | unknown | — | 25 | Instituto Ecuatoriano de Enfermedades DigestivasOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT05168254 | Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer | unknown | — | 50 | Ruijin HospitalOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT05163977 | Pancreatico Enteric Anastomosis Post Pancreaticoduodenectomy(PEAPP) | unknown | N/A | 90 | Cairo UniversityOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02944006 | Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling | unknown | — | 29 | Seoul National University HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05148143 | RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor(RALOXBTC) | unknown | Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05141656 | Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center | unknown | — | 20,000 | RenJi HospitalOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT05138159 | A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05138302 | A Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients | unknown | — | 1,000 | RenJi HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT04810910 | Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | unknown | Phase 1 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05101772 | 25G and 22G Puncture Needles | unknown | — | 73 | Peking Union Medical College HospitalOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT02232932 | Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma(TRANSPHIL) | unknown | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05100329 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer | unknown | Phase 2 | 38 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT05009966 | Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor | unknown | Phase 1 | 272 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04089150 | MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease(MASTERPLAN) | unknown | Phase 2 | 120 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 26, 2022source: clinicaltrials